Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thoratec submits amended HeartMate PMA:

This article was originally published in Clinica

Executive Summary

Thoratec has filed an amendment to the PMA seeking approval of its HeartMate II LVAS (left ventricular assist system) for bridge-to-transplantation (BTT). The Pleasanton, California firm submitted the original regulatory application in December 2006. The updated filing contains data from 279 further patients and is intended to address safety and efficacy queries raised by the US FDA. The company also completed enrolment of 200 patients in the destination therapy (DT) arm of its HeartMate II trial, which will be used to seek approval for long-term use of the device. Thoratec received clearance to enrol an additional 60 patients in both the DT and BTT arms.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048565

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel